Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of three lots of 20-valent pneumococcal conjugate vaccine in adults; study completed with posted results in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine, 20-valent)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-11-04